Source comparison
Dosing Schedules: Loading Phase vs Maintenance Phase Protocols
TB-500 research protocols typically follow a two-phase structure: loading phase (high-frequency, high-dose administrations to saturate tissue) and maintenance phase (lower-frequency administrations to sustain plasma levels). The number of doses per vial change
This comparison does not assign a generated winner or score.
- TB-500 research protocols typically follow a two-phase structure: loading phase (high-frequency, high-dose administrations to saturate tissue) and maintenance phase (lower-frequency administrations to sustain plasma levels). The number of doses per vial changes dramatically between phases because per-administration targets shift from 2–5mg down to 500mcg–2mg.
- Loading phase protocols in musculoskeletal injury models commonly administer 2–5mg TB-500 twice weekly for 4–6 weeks. A 5mg vial at 2.5mg per dose yields exactly two administrations, meaning researchers require 8–12 vials to complete a standard loading protocol. A 10mg vial reconstituted with 4mL bacteriostatic water (yielding 2.5mg/mL) provides four 2.5mg doses, reducing vial count requirements by half. Maintenance phase protocols drop to 500mcg–2mg once weekly or biweekly, meaning a single 5mg vial reconstituted to 1mg/mL (5mL bacteriostatic water) yields five to ten maintenance doses depending on target amount.
- The half-life of TB-500 is approximately 7–10 days in circulation, though tissue depot effects extend local activity beyond plasma clearance. This pharmacokinetic profile supports weekly or twice-weekly dosing rather than daily administration. Protocols attempting daily low-dose TB-500 (e.g., 200–500mcg/day) increase vial consumption without proportional benefit because tissue saturation plateaus—the receptor-mediated uptake in injured tissue has a ceiling that excess circulating peptide doesn't overcome. Researchers tracking collagen deposition and angiogenesis markers in tendon repair models consistently observe that 2mg twice weekly produces comparable histological outcomes to 5mg twice weekly, but with 60% lower peptide consumption per study.
- Our experience across hundreds of research protocols shows that dose creep—gradually increasing per-administration amounts without recalculating vial yield—is the primary driver of unexpected peptide depletion mid-study. Establish your per-dose target before reconstitution and mark each vial with concentration and dose volume to prevent math errors during administration.